MX347901B - Uso y composicion para tratar la demencia. - Google Patents

Uso y composicion para tratar la demencia.

Info

Publication number
MX347901B
MX347901B MX2014004035A MX2014004035A MX347901B MX 347901 B MX347901 B MX 347901B MX 2014004035 A MX2014004035 A MX 2014004035A MX 2014004035 A MX2014004035 A MX 2014004035A MX 347901 B MX347901 B MX 347901B
Authority
MX
Mexico
Prior art keywords
achei
selective
patient
anticholinergic agent
type dementia
Prior art date
Application number
MX2014004035A
Other languages
English (en)
Inventor
Thomas N Chase
Kathleen E Clarence-Smith
Original Assignee
Chase Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39535697&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX347901(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chase Pharmaceuticals Corp filed Critical Chase Pharmaceuticals Corp
Publication of MX347901B publication Critical patent/MX347901B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4747—Quinolines; Isoquinolines spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describe un método para incrementar la dosis máxima tolerada y de esta manera la eficacia de un inhibidor de acetilcolina esterasa (AChEI) en un paciente que sufre de demencia del tipo Alzheimer al disminuir los efectos adversos concomitantes por medio de la administración del AChEI en combinación con un agente anticolinérgico, periférico, no selectivo, por lo cual se logra una inhibición mejorada de acetilcolina esterasa en el CNS del paciente y el alivio de los síntomas de demencia del tipo Alzheimer en el paciente se mejora por lo cual a un grado mayor. También se describe el uso de un agente anticolinérgico, periférico, no selectivo (nsPAChA) para la preparación de una composición farmacéutica para incrementar la dosis máxima tolerada y de esta manera la eficacia de un inhibidor de acetilcolina esterasa (AChEI) en un paciente que sufre de demencia del tipo Alzheimer y composiciones farmacéuticas que comprenden un agente anticolinérgico periférico, no selectivo de la fórmula II como se ilustra en la descripción y un inhibidor de acetilcolina esterasa.
MX2014004035A 2008-03-27 2009-03-17 Uso y composicion para tratar la demencia. MX347901B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08005750 2008-03-27
PCT/US2009/001662 WO2009120277A1 (en) 2008-03-27 2009-03-17 Use and composition for treating dementia

Publications (1)

Publication Number Publication Date
MX347901B true MX347901B (es) 2017-05-18

Family

ID=39535697

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2014004035A MX347901B (es) 2008-03-27 2009-03-17 Uso y composicion para tratar la demencia.
MX2013009019A MX344177B (es) 2008-03-27 2009-03-17 Uso y composicion para tratar la demencia.
MX2010010460A MX2010010460A (es) 2008-03-27 2009-03-17 Uso y composicion para tratar la demencia.

Family Applications After (2)

Application Number Title Priority Date Filing Date
MX2013009019A MX344177B (es) 2008-03-27 2009-03-17 Uso y composicion para tratar la demencia.
MX2010010460A MX2010010460A (es) 2008-03-27 2009-03-17 Uso y composicion para tratar la demencia.

Country Status (10)

Country Link
US (5) US8404701B2 (es)
EP (3) EP3178477A1 (es)
JP (3) JP5647099B2 (es)
AU (1) AU2009229372C1 (es)
CA (1) CA2718411C (es)
DK (1) DK2271218T3 (es)
ES (1) ES2634421T3 (es)
MX (3) MX347901B (es)
PL (1) PL2271218T3 (es)
WO (1) WO2009120277A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8969402B2 (en) 2006-11-15 2015-03-03 Steven A. Rich Combined acetylcholinesterase inhibitor and quaternary ammonium antimuscarinic therapy to alter progression of cognitive diseases
AU2009229372C1 (en) * 2008-03-27 2017-02-02 Chase Pharmaceuticals Corporation Use and composition for treating dementia
US20110201597A1 (en) 2008-03-27 2011-08-18 Chase Thomas N Method and composition for treating alzheimer-type dementia
HUE044653T2 (hu) 2009-07-22 2019-11-28 PureTech Health LLC Készítmények olyan rendellenességek kezelésére, amelyek muszkarin-receptor aktiválással enyhíthetõk
MX345236B (es) 2009-09-18 2017-01-23 Chase Pharmaceuticals Corp Metodo y composicion para tratar la demencia de tipo alzheimer.
JP2011213606A (ja) * 2010-03-31 2011-10-27 Sawai Pharmaceutical Co Ltd ドネペジルを含有する固形製剤の製造方法
JP2011213695A (ja) * 2010-04-02 2011-10-27 Taisho Pharm Ind Ltd ドネペジル塩酸塩含有口腔内速崩壊錠
IN2015DN01706A (es) * 2012-09-05 2015-05-22 Chase Pharmaceuticals Corp
EP3242659A4 (en) 2015-01-09 2018-09-12 Chase Pharmaceuticals Corporation Oxybutynin transdermal therapeutic system combination
US10307409B2 (en) * 2015-03-06 2019-06-04 Chase Pharmaceuticals Corporation Muscarinic combinations and their use for combating hypocholinergic disorders of the central nervous system
EP3265128A4 (en) 2015-03-06 2018-09-12 Chase Pharmaceuticals Corporation Oxybutynin transdermal therapeutic system muscarinic agonist combination
WO2016144727A1 (en) * 2015-03-06 2016-09-15 Chase Pharmaceuticals Corporation Peripheral-anticholinergic muscarinic agonist combination
AU2016279798B2 (en) 2015-06-15 2021-07-08 Qaam Pharmaceuticals, Llc Glycopyrronium fatty acid salts and methods of making same
CA2992731A1 (en) * 2015-07-20 2017-01-26 Chase Pharmaceuticals Corporation Muscarinic combination of a selective m2-antagonist and a peripheral non-selective antagonist for treating hypocholinergic disorders
CA2996717A1 (en) 2015-09-11 2017-03-16 Chase Pharmaceuticals Corporation Muscarinic combination and its use for combating hypocholinergic disorders of the central nervous system
WO2017147104A1 (en) * 2016-02-24 2017-08-31 Chase Pharmaceuticals Corporation Muscarinic m2-antagonist combinations
US10479706B2 (en) * 2016-06-03 2019-11-19 Katz Water Tech, Llc Apparatus, method and system for desalinating water
WO2018081508A1 (en) * 2016-10-28 2018-05-03 Chase Pharmaceutical Corporation Memantine combinations and use
BR112020021173A2 (pt) * 2018-04-17 2021-01-19 Lts Lohmann Therapie-Systeme Ag Sistema terapêutico transdérmico para a administração transdérmica de solifenacina
MX2021003621A (es) 2018-09-28 2022-04-13 Karuna Therapeutics Inc Composiciones y metodos para tratar trastornos mejorados por medio de activacion de receptor muscarinico.
US20240024261A1 (en) * 2020-09-21 2024-01-25 Dr. Raymond Lab Inc Pharmaceutical composition for improving cognitive ability or enhancing memory

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB795758A (en) 1955-08-22 1958-05-28 Pfizer & Co C Amino esters and the preparation thereof
US3480626A (en) 1967-05-18 1969-11-25 Chem Fab Dr R Pfleger Certain azoniaspironortropine derivatives
GB1204580A (en) 1968-10-05 1970-09-09 Aspro Nicholas Ltd Pharmaceutical dosage forms
US3576388A (en) 1968-12-05 1971-04-27 Stauffer Wacker Silicone Corp Electrical cable
DD106643A1 (es) 1973-07-12 1974-06-20
US4965074A (en) 1985-03-05 1990-10-23 Ciba-Geigy Corporation Method of treating memory impairment
US4663318A (en) 1986-01-15 1987-05-05 Bonnie Davis Method of treating Alzheimer's disease
US4798841A (en) 1987-03-31 1989-01-17 Warner-Lambert Company Tetrahydropyridine oxime cholinergic agents and method of treatment
GB8717446D0 (en) 1987-07-23 1987-08-26 Merck Sharp & Dohme Chemical compounds
US5382600A (en) 1988-01-22 1995-01-17 Pharmacia Aktiebolag 3,3-diphenylpropylamines and pharmaceutical compositions thereof
US4937239A (en) 1989-02-13 1990-06-26 Warner-Lambert Company Azabicycloalkane oxime & azabicycloalkene oxime muscarinic agents
US5852029A (en) 1990-04-10 1998-12-22 Israel Institute For Biological Research Aza spiro compounds acting on the cholinergic system with muscarinic agonist activity
NO2005012I1 (no) 1994-12-28 2005-06-06 Debio Rech Pharma Sa Triptorelin og farmasoytisk akseptable salter derav
GB9612710D0 (en) 1996-06-18 1996-08-21 Pfizer Ltd Method of treatment
US6410747B1 (en) 1997-07-09 2002-06-25 The United States Of America As Represented By The Department Of Health And Human Services Highly selective butyrylcholinesterase inhibitors for the treatment and diagnosis of alzheimer's disease and dementias
EP0976404A3 (en) 1998-07-30 2001-06-27 Pfizer Products Inc. A pharmaceutical composition for the prevention and treatment of diseases of cognitive dysfunction in a mammal
CA2310926C (en) 2000-04-03 2002-10-15 Janssen Pharmaceutica N.V. A use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease
EP1408965A2 (en) * 2001-02-08 2004-04-21 Schering Corporation Use of dual h3/m2 antagonists with a bipiperidinic structure in the treatment of cognition deficit disorders
US8216609B2 (en) * 2002-08-05 2012-07-10 Torrent Pharmaceuticals Limited Modified release composition of highly soluble drugs
US7427280B2 (en) * 2002-09-06 2008-09-23 Medtronic, Inc. Method, system and device for treating disorders of the pelvic floor by delivering drugs to various nerves or tissues
US6974820B2 (en) 2002-11-06 2005-12-13 Bridge Pharma, Inc. Methods for treating urinary incontinence and other disorders using trospium
CN1520818A (zh) 2003-02-09 2004-08-18 山东绿叶天然药物研究开发有限公司 治疗老年性痴呆的胆碱酯酶抑制剂药物组合物
US8299062B2 (en) 2003-09-17 2012-10-30 Franklin Volvovitz Pharmaceutical compositions and methods for preventing, treating, or reversing neuronal dysfunction
GB0322140D0 (en) 2003-09-22 2003-10-22 Pfizer Ltd Combinations
WO2005073198A1 (en) * 2004-01-16 2005-08-11 Wyeth Heterocyclic sulfonamide inhibitors of beta amyloid production containing an azole
CA2555399A1 (en) 2004-02-20 2005-09-01 Novartis Ag Dpp-iv inhibitors for treating neurodegeneration and cognitive disorders
AR051950A1 (es) 2004-11-10 2007-02-21 Osmotica Pharmaceutical Argent Comprimido multicapa con capas que se separan
US8481565B2 (en) 2004-12-27 2013-07-09 Eisai R&D Management Co., Ltd. Method for stabilizing anti-dementia drug
US7390816B2 (en) 2005-06-21 2008-06-24 Bridge Pharma, Inc. Methods for treating urinary incontinence in patients suffering from memory disorders
US20070004766A1 (en) 2005-07-01 2007-01-04 Aberg A K G Methods for relaxation of smooth muscle contractions using Trospium
US20070224259A1 (en) 2005-09-21 2007-09-27 Gupta Anil K Anti-inflammatory pharmaceutical composition
JP5362360B2 (ja) 2005-10-11 2013-12-11 イッサム リサーチ ディヴェロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム 経鼻投与用組成物
JP2009534385A (ja) * 2006-04-21 2009-09-24 ワイス キラル的に純粋なアミノアルコール中間体、それらの誘導体の製造、及びそれらの使用
EP2399577A1 (en) * 2006-09-12 2011-12-28 Adolor Corporation Use of N-containing spirocompounds for the enhancement of cognitive function
US20080090808A1 (en) 2006-10-17 2008-04-17 Franklin Volvovitz Pharmaceutical compositions and methods for preventing, treating, or reversing neuronal dysfunction
US8097633B2 (en) * 2006-11-15 2012-01-17 Rich Steven A Uses for quaternary ammonium anticholinergic muscarinic receptor antagonists in patients being treated for cognitive impairment or acute delirium
AU2009229372C1 (en) * 2008-03-27 2017-02-02 Chase Pharmaceuticals Corporation Use and composition for treating dementia
MX345236B (es) * 2009-09-18 2017-01-23 Chase Pharmaceuticals Corp Metodo y composicion para tratar la demencia de tipo alzheimer.

Also Published As

Publication number Publication date
MX2010010460A (es) 2010-12-15
US20190091214A1 (en) 2019-03-28
AU2009229372B2 (en) 2014-09-25
DK2271218T3 (en) 2017-09-11
EP2271218B1 (en) 2017-05-24
EP4088717A1 (en) 2022-11-16
AU2009229372C1 (en) 2017-02-02
MX344177B (es) 2016-12-08
EP2271218A1 (en) 2011-01-12
US9044472B2 (en) 2015-06-02
JP5647099B2 (ja) 2014-12-24
JP2011518776A (ja) 2011-06-30
US8404701B2 (en) 2013-03-26
PL2271218T3 (pl) 2017-10-31
US20110021503A1 (en) 2011-01-27
CA2718411A1 (en) 2009-10-01
EP3178477A1 (en) 2017-06-14
JP2016179980A (ja) 2016-10-13
CA2718411C (en) 2016-02-16
JP2014114295A (ja) 2014-06-26
EP2271218A4 (en) 2011-05-18
US20130158012A1 (en) 2013-06-20
US20140275036A1 (en) 2014-09-18
WO2009120277A1 (en) 2009-10-01
AU2009229372A1 (en) 2009-10-01
US20150224096A1 (en) 2015-08-13
JP6427522B2 (ja) 2018-11-21
ES2634421T3 (es) 2017-09-27

Similar Documents

Publication Publication Date Title
MX344177B (es) Uso y composicion para tratar la demencia.
CA2773592C (en) Method and composition for treating alzheimer-type dementia
NZ619076A (en) Isoxazolines as inhibitors of fatty acid amide hydrolase
WO2008157537A3 (en) Compositions and methods of use for treating or preventing lipid related disorders
MX2009003727A (es) Acidos y esteres boronicos como inhibidores de amida hidrolasa de acido graso.
MX2020002113A (es) Composicion neuroprotectora anticolinergica y metodos.
MX2014000341A (es) Novedosos derivados de trifluoro-metil-oxadiazol y su uso en el tratamiento de enfermedades.
EA201170061A1 (ru) Новые производные фенилимидазола в качестве ингибиторов фермента pde10a
EA201200390A1 (ru) Макроциклические ингибиторы сериновых протеаз гепатита с
EA200870423A1 (ru) Производные триазолпиразинов, применимые в качестве противораковых агентов
WO2007143607A3 (en) Method of treating atrophic vaginitis
IN2012DN01233A (es)
MX342477B (es) Compuestos y su uso como inhibidores de sitio beta de escision de enzima (bace).
MX2012000488A (es) Terapia de combinacion para el tratamiento de la diabetes.
WO2007128086A3 (en) Novel viral replication inhibitor
PH12013502370A1 (en) Multiheteroaryl compounds as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases
MX2012014301A (es) Inhibidores macrociclicos de serina proteasa de hepatitis c.
MX2012003171A (es) Novedosos inhibidores macrociclicos de la replicacion del virus de hepatitis c.
MD20140044A2 (ro) 2-Tiopirimidinone şi utilizarea lor pentru tratamentul afecţiunilor cardiovasculare
NO20084826L (no) Ny administrasjonsform av racecadotril
NI201100024A (es) [ 4 - ( 5 - aminometil - 2 - fluoro - fenil ) - piperidin -1- il ] - [ 17-fluor0 - 1 - (2 - metoxi - etil ) - 4 - trifluorometoxi - 1h - indol - 3 - il] - metanona como un inhibidor de la triptasa de mastocitos.
BR112012024708A2 (pt) composição de compostos orgânicos
EP2417115A4 (en) FATTY ACID AMIDE HYDROLASE INHIBITORS
EA201001100A1 (ru) Фармацевтическая композиция на основе гепатопротектора и пребиотика, получение и применение
MY156278A (en) Disubstituted [4-(5-aminomethyl-phenyl)-piperidin-1-yl]-1h-indol-3-yl]-methanones